XWELL (NASDAQ:XWEL) Given New $7.00 Price Target at HC Wainwright

XWELL (NASDAQ:XWEL) had its price objective raised by research analysts at HC Wainwright to $7.00 in a research report issued to clients and investors on Friday, November 17th, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 239.81% from the company’s previous close.

XWELL Stock Up 3.0 %

NASDAQ:XWEL opened at $2.06 on Friday. The company’s 50 day moving average is $2.15 and its 200-day moving average is $3.81. XWELL has a 12 month low of $1.39 and a 12 month high of $12.20. The firm has a market cap of $8.61 million, a price-to-earnings ratio of -0.25 and a beta of 2.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of XWEL. Bank of New York Mellon Corp acquired a new stake in shares of XWELL in the first quarter valued at about $32,000. Integrated Wealth Concepts LLC bought a new stake in XWELL during the 1st quarter valued at approximately $75,000. Geode Capital Management LLC bought a new stake in XWELL during the 1st quarter valued at approximately $376,000. Finally, BlackRock Inc. bought a new position in XWELL in the 1st quarter worth approximately $667,000. Institutional investors and hedge funds own 10.58% of the company’s stock.

About XWELL

XWELL, Inc, a health and wellness services company, provides spa services at airports. It operates through XpresSpa, XpresTest, Treat, and HyperPointe segments. The company offers spa services, including massage, and nail and skin care, as well as spa and travel products; and retail products. It also provides diagnostic COVID-19 tests at XpresCheck wellness centers in airports; and other medical diagnostic testing services.